NCT-06326411

Phase 1, open label single-arm two-part study to investigate safety, pharmacokinetics, andpreliminary efficacy of pan-RAF/MEK glue NST-628 oral tablets in subjects with solid tumorsharboring genetic alterations in the MAPK pathway and with other solid tumors

This is a Phase 1, open-label, single-arm study with two parts to investigate the safety, how the body processes the drug, and the early effectiveness of a new drug, NST-628 oral tablets in patients with solid tumors that have genetic changes in the MAPK pathway, as well as other types of solid tumors. The goal is to determine how safe the drug is and how well it might work in treating these cancers. In this study, all participants will receive the same treatment, and researchers will first focus on its safety before assessing its effectiveness.

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

Single Arm Study: A study where sample of individuals with the targeted medical condition is given the experimental therapy and then followed over time to observe their response.

MAPK pathway: The MAPK pathway is a communication system inside cells that regulates their growth, and when it malfunctions, it can contribute to cancer development

open-label: Patients know which treatments are being given to them

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06326411

Clinical Trial Site: Columbia

To see all available clinical trials click here.